Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

The Lancet Oncology

Volumn 18, Issue 6, 2017, Pages 743-754

  Krop, Ian E ^a   Kim, Sung Bae ^b   Martin, Antonio Gonzalez ^c   LoRusso, Patricia M ^d   Ferrero, Jean Marc ^e   Badovinac Crnjevic, Tanja ^f   Hoersch, Silke ^f   Smitt, Melanie ^g   Wildiers, Hans ^h  

^a HARVARD MEDICAL SCHOOL   (United States)

^b University of Ulsan College of Medicine   (South Korea)

^c MD ANDERSON CANCER CENTER   (Spain)

^d YALE UNIVERSITY MEDICAL CENTER   (United States)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g GENENTECH INC   (United States)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LAPATINIB; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE; TAXANE; TAXOID;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLEEDING; CANCER GRADING; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CELLULITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DYSPNEA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FUNCTIONAL STATUS; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; LEUKOPENIA; LIMB PAIN; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; XEROSTOMIA; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CHEMICALLY INDUCED; CHEMISTRY; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; EARLY TERMINATION OF CLINICAL TRIAL; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RETREATMENT; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; BRIDGED-RING COMPOUNDS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; DIARRHEA; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HEMORRHAGE; HUMANS; MALE; MAYTANSINE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PRACTICE PATTERNS, PHYSICIANS'; QUINAZOLINES; RECEPTOR, ERBB-2; RETREATMENT; SURVIVAL RATE; TAXOIDS; THROMBOCYTOPENIA; TRASTUZUMAB;

EID: 85019974512     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30313-3     Document Type: Article

References (28)

1. Lewis Phillips, GD, Li, G, Dugger, DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68 (2008), 9280–9290.
2. Verma, S, Miles, D, Gianni, L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367 (2012), 1783–1791.
3. Diéras, V, Miles, D, Verma, S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol, 2017 published online May 16 http://dx.doi.org/10.1016/S1470-2045(17)30312-1.
4. Krop, IE, Kim, SB, González-Martín, A, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15 (2014), 689–699.
5. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
6. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events, version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf (accessed Feb 23, 2016).
7. European Commission. Kadcyla 100 mg powder for concentrate for solution for infusion—summary of product characteristics. https://ec.europa.eu/health/documents/community-register/2013/20131115127009/anx_127009_en.pdf, Jan 13, 2017 (accessed May 3, 2017).
8. Genentech, Inc. Kadcyla [prescribing information]. South San Francisco, CA. https://www.gene.com/download/pdf/kadcyla_prescribing.pdf, 2016 (accessed May 3, 2017).
9. Rossi, S, Basso, M, Strippoli, A, et al. Hormone receptor status and HER2 expression in primary breast cancer compared with synchronous axillary metastases or recurrent metastatic disease. Clin Breast Cancer 15 (2015), 307–312.
10. Guarneri, V, Dieci, MV, Barbieri, E, et al. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol 24 (2013), 2990–2994.
11. Gerlinger, M, Rowan, AJ, Horswell, S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366 (2012), 883–892.
12. von Minckwitz, G, du Bois, A, Schmidt, M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 27 (2009), 1999–2006.
13. Pivot, X, Manikhas, A, Żurawski, B, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 33 (2015), 1564–1573.
14. Harbeck, N, Huang, CS, Hurvitz, S, et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol 17 (2016), 357–366.
15. Blackwell, KL, Burstein, HJ, Storniolo, AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28 (2010), 1124–1130.
16. Geyer, CE, Forster, J, Lindquist, D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355 (2006), 2733–2743.
17. André, F, O'Regan, R, Ozguroglu, M, et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15 (2014), 580–591.
18. André, F, Hurvitz, S, Fasolo, A, et al. Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol 34 (2016), 2115–2124.
19. Goel, S, Wang, Q, Watt, AC, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell 29 (2016), 255–269.
20. García-García, C, Ibrahim, YH, Serra, V, et al. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 18 (2012), 2603–2612.
21. Saura, C, Bendell, J, Jerusalem, G, et al. Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res 20 (2014), 1935–1945.
22. Kim, SB, Wildiers, H, Krop, IE, et al. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs treatment of physician's choice in previously treated HER2-positive advanced breast cancer. Int J Cancer 139 (2016), 2336–2342.
23. Dzimitrowicz, H, Berger, M, Vargo, C, et al. T-DM1 activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab. J Clin Oncol 29 (2016), 3511–3517.
24. Krop, IE, Lin, NU, Blackwell, K, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 26 (2015), 113–119.
25. Bartsch, R, Berghoff, AS, Vogl, U, et al. Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clin Exp Metastasis 32 (2015), 729–737.
26. Jacot, W, Pons, E, Frenel, JS, et al. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res Treat 157 (2016), 307–318.
27. Montemurro, F, Ellis, P, Delaloge, S, et al. Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: exploratory subgroup analysis from the KAMILLA study. Cancer Res, 4, 2017, P1-12-10.
28. Diéras, V, Harbeck, N, Budd, GT, et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol 32 (2014), 2750–2757.